Humana stock has delivered a strong 41.8% return over the past year, yet its valuation checks and market multiples point to a more mixed picture rather than a straightforward bargain or bubble.

• Over the last 12 months, Humana has returned 41.8%, which puts recent share price weakness into context for investors assessing whether the move has already priced in a lot of good news.
• Humana's valuation can be influenced by how consistently it converts revenue into cash flow, while any sustained pressure on margins or higher capital needs may weigh on what investors are willing to pay for the stock.
• On Simply Wall St's checks, Humana screens as undervalued on some measures, but with a mixed overall picture since it only passes 3 of 6 valuation checks. You can see this in more detail at 3 of 6 valuation checks.

The stock's next move may depend on whether Humana's current price already reflects the stronger share price performance of the last year or still leaves room for further upside based on its fundamentals.

Is Humana Still Cheap on Earnings?

The P/E ratio is a common way to assess what investors are paying for each dollar of Humana's earnings. For a mature healthcare insurer like Humana, this earnings based view is often a key reference point.

Humana currently trades on a P/E of 38.8x. That sits above the broader Healthcare industry average of 26.9x and also above the peer group average of 29.4x. However, Simply Wall St's fair P/E ratio for Humana is higher at 45.8x. This fair ratio reflects the model's view of what investors might pay given Humana's profile within the sector.

The gap between the current 38.8x P/E and the 45.8x fair ratio suggests the market is applying a lower earnings multiple than the model indicates could be justified. For investors who lean on earnings based valuation, Humana therefore screens as attractively priced relative to this tailored benchmark despite trading at a premium to the wider industry.

On the P/E multiple, Humana stock appears undervalued relative to the fair ratio implied by its earnings profile.

The Humana Narrative: What Would Justify Today's Price?

Simply Wall St Narratives pick up where the P/E puzzle for Humana leaves off and describe which paths for growth, margins and earnings would need to occur for the stock to appear much stronger or weaker than today's price. Each narrative ties its number to a clear view on how Humana's growth, profitability and risks might evolve, and you can revisit these views as new results and disclosures are released.

Community views on Humana sit far apart, with one camp focused on margin rebuild potential and another on rising regulatory pressure.

Bull case: 27% undervalued

"Ongoing expansion and maturation of the CenterWell platform (primary care, home health, and pharmacy) is expected to boost per-member-per-month payments and operating leverage…"

Bear case: 72% overvalued

"Across the industry, regulators are sharpening their focus on how health plans document risk adjustment data and apply prior authorization standards…"

Do you think there's more to the story for Humana? Head over to our Community to see what others are saying!

The Bottom Line

Humana screens as undervalued on its tailored P/E yardstick, even though the broader valuation checks are mixed rather than clearly cheap or expensive. That makes the current setup less about a single clear signal and more about how much confidence you have in the durability of Humana's earnings power. The crux of the debate is whether margins can strengthen in the face of regulatory scrutiny and capital needs, or whether those pressures limit the valuation multiple investors are willing to pay from here.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.